<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="discussion"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">J. Pediatr</journal-id><journal-title-group><journal-title>The Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="ppub">0022-3476</issn><issn pub-type="epub">1097-6833</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7308002</article-id><article-id pub-id-type="publisher-id">S0022-3476(20)30760-5</article-id><article-id pub-id-type="doi">10.1016/j.jpeds.2020.06.057</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Rowley</surname><given-names>Anne H.</given-names></name><degrees>M.D.</degrees><email>a-rowley@northwestern.edu</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1">Professor of Pediatrics and of Microbiology and Immunology Northwestern University Feinberg School of Medicine The Ann &#x00026; Robert H. Lurie Children&#x02019;s Hospital of Chicago Chicago, IL</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Correspondence: Anne H. Rowley, M.D. The Ann &#x00026; Robert H. Lurie Children&#x02019;s Hospital of Chicago 225 E Chicago Avenue, Box #205 Chicago, IL 60611 <email>a-rowley@northwestern.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>22</day><month>6</month><year>2020</year></pub-date><history><date date-type="received"><day>11</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>16</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p id="p0010">In late April 2020, alarming news emerged from Europe that a group of children with evidence of recent SARS-CoV-2 infection had developed a severe illness, manifesting fever, hypotension requiring inotropic support, severe abdominal pain, and myocardial dysfunction with marked elevation in cardiac damage markers. This syndrome has been named Pediatric Multisystem Inflammatory Syndrome in Europe, and Multisystem Inflammatory Syndrome in Children (MIS-C) by the U.S. Centers for Disease Control (CDC). As case series began to be reported, the similarities in the clinical features among the cases were striking, as were the frequent additional laboratory features of lymphopenia, thrombocytopenia, and cytokine storm with marked elevation in serum inflammatory markers including interleukin-6 (IL-6 )(1-6,<xref rid="bib6a" ref-type="bibr">6A</xref>,<xref rid="bib6b" ref-type="bibr">6B</xref>). Most of these children recovered, although infrequently patients have required extracorporeal membrane oxygenation, with a fatal outcome from complications of this therapy reported rarely (3,<xref rid="bib6a" ref-type="bibr">6A</xref>). Patients were managed in different ways, often with corticosteroid therapy, intravenous gammaglobulin, and, less often, anti-cytokine therapies, and the vast majority appeared to require intensive care therapy only for a matter of days, regardless of the management strategy (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib6a" ref-type="bibr">6A</xref>,<xref rid="bib6b" ref-type="bibr">6B</xref>). Some patients had one or more clinical features that can be observed in many illnesses of childhood including Kawasaki disease, such as conjunctival injection, oral erythema, and rash. Classic KD diagnostic criteria were rarely present. Moreover, the median age of the cases was 9-10 years in the largest series reported to date (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib7" ref-type="bibr">7</xref>), which is in marked contrast to KD, which occurs predominately in children <underline>&#x0003c;</underline>5 years of age and with a peak incidence at &#x0223c;10 months of age (<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>). Asian children have the highest attack rates of KD, whereas the highest rates of MIS-C have been in children of African descent (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib10" ref-type="bibr">10</xref>). These marked epidemiologic differences make it clear that the two conditions are not the same.</p><p id="p0015">Because of a concern that MIS-C might potentially encompass a wider range of clinical features than those observed in the reported cases, the CDC developed a broad case definition. Unfortunately, the case definition as it currently stands is problematic, because patients with many infectious and inflammatory conditions of childhood that are not MIS-C fulfill the case definition. This includes patients with acute COVID-19 infection (eg, acute infection with fever, rash, diarrhea, and a minimally elevated C-reactive protein level), classic KD (e.g., a child with KD who has rash as one of the diagnostic features and mild hepatitis or diarrhea), other viral infections (e.g. one of many that could cause fever, rash, cough, and an increase in neutrophils in peripheral blood), systemic onset juvenile idiopathic arthritis (e.g., fever, rash, an increase in neutrophils in peripheral blood, elevated acute phase reactants), and so on. Moreover, on my recent clinical service, I noted an increase in patient transfers from referring hospitals of children with low grade fever for one day, rash, and mild abdominal discomfort, for evaluation for possible MIS-C. These children arrived appearing well, with completely normal blood pressure and heart rate and minimally elevated acute phase reactants. Presumably, all the media publicity about MIS-C is raising concern among practitioners about missing this diagnosis, potentially resulting in an increase in hospital admissions for routine minor childhood illnesses, and a likely inflated number of reported cases. Moreover, a rapid or presumptive diagnosis of MIS-C, which remains uncommon, also has the potential to result in premature diagnostic closure in children who fulfill the broad case definition but in reality have a potentially life-threatening, non-MIS-C illness.</p><p id="p0020">It is problematic that some similar clinical features of MIS-C and incomplete KD can lead to diagnostic uncertainty in individual patients. This scenario reminds me of my clinical experience in the late 1980s and early 1990s in Chicago when we were experiencing a different viral epidemic, due to measles. During that time, it was startling to see how closely the clinical features of KD resembled those of measles. Our approach at that time to differentiate the conditions was to perform a measles IgM antibody test, run daily in our hospital during the epidemic, and if the test was negative, treat the patient for KD. Measles is one of the few infectious diseases that virtually always is symptomatic, so a positive test result confirmed the diagnosis. The present COVID-19 epidemic does not offer such a straightforward solution to the diagnostic dilemma. Not only is there no diagnostic test for KD at present, but asymptomatic or mildly symptomatic SARS-CoV-2 infection is prevalent enough in children in many areas of the U.S. and abroad at the present time that even a positive RT-PCR or serologic test for SARS-CoV-2 antibody does not necessarily mean that a child&#x02019;s presenting illness is related to SARS-CoV-2. With routine RT-PCR screening of hospitalized patients, we find occasional positive results in children admitted with fractures, for routine surgical procedures, and with a variety of other clinical problems not related to SARS-CoV-2 infection. In addition, antibody positivity is very likely to be increasing over time in the population. Understandably, diagnostic confusion can result, and incorrect diagnoses may be assigned. To add to this confusion, some patients with MIS-C are reported to have developed mild coronary artery dilation (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib10" ref-type="bibr">10</xref>) or rarely, aneurysms (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib7" ref-type="bibr">7</xref>). That mild transient coronary artery dilation can develop as a result of cytokine storm with high IL-6 levels has been demonstrated in systemic onset juvenile idiopathic arthritis (<xref rid="bib11" ref-type="bibr">11</xref>), and mild transient coronary dilation could be the result of a similar cytokine storm in MIS-C. Persistent coronary artery aneurysms and their complications, however, have previously only been attributed to KD in pediatric patients. Because of the clinical similarities in the two conditions, it is possible that patients reported as having MIS-C with persisting aneurysms actually had KD. Fortunately, patients with KD and MIS-C both improve with intravenous gammaglobulin and corticosteroid therapy, although the efficacy of any therapy for MIS-C is evolving and is as yet is unproven. If SARS-CoV-2 can result in persisting coronary artery aneurysms, it would be noteworthy, as it would be the first virus proved to do so.</p><p id="p0025">For patients in whom MIS-C and KD are being considered, some clinical and laboratory features of the two conditions may help in discerning the correct diagnosis. Abdominal pain significant enough to prompt advanced imaging and surgical consultation occurs rarely in KD (<xref rid="bib10a" ref-type="bibr">10a</xref>) but is characteristic of MIS-C. Lymphopenia is a typical finding in MIS-C and is reported rarely in KD; the more severe the lymphopenia, the more likely the diagnosis is MIS-C. Although NT-pro-BNP is a biomarker of potential value in KD and some patients have been reported to have levels as high as 7,000 pg/mL (<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>), the extent of the elevation in KD generally is lower than in MIS-C, for which values in excess of 10,000 pg/mL often are reported; the higher the NT-pro-BNP level, the more likely the diagnosis is MIS-C. Myocardial dysfunction as assessed by echocardiography is common in MIS-C and is rare in KD..</p><p id="p0030">Some investigators have proposed that MIS-C, while having very different epidemiologic and some different laboratory features compared with KD, could provide etiologic clues that KD may result from infection with a coronavirus (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib10" ref-type="bibr">10</xref>). The <xref rid="tbl1" ref-type="table">Table</xref>
outlines some differing features of KD and coronavirus infections that make an etiologic relationship unlikely. Moreover, if SARS-CoV-2 or a closely related virus was a KD etiologic agent, one would expect the epidemiology of MIS-C and KD to be similar. Of note, MIS-C cases have not been observed in China (<xref rid="bib14" ref-type="bibr">14</xref>) or Japan, countries with the highest prevalence of KD in the world, which surely should have been expected if there was an etiologic relationship between KD and MIS-C.<table-wrap position="float" id="tbl1"><label>Table</label><caption><p>Distinct Features of Kawasaki Disease and Coronavirus Infections</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Kawasaki Disease</th><th>Coronavirus Infections</th></tr></thead><tbody><tr><td/><td/></tr><tr><td>No virus can be isolated from cultures of clinical specimens (<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>)</td><td>Virus can be isolated from cultures of clinical specimens</td></tr><tr><td>No coronavirus is identified by high throughput RNA sequencing of tissues from KD patients (<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>)</td><td>Virus can be identified by high throughput RNA sequencing of tissues from infected patients</td></tr><tr><td>No signal exists for serologic cross reactivity with coronaviruses, even using new highly sensitive VirScan method (<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>)</td><td>Serologic cross reactivity occurs with other coronaviruses, particularly those in the same subfamily (<xref rid="bib25" ref-type="bibr">25</xref>)</td></tr><tr><td>Recurrence is rare; disease is rare in adolescents and adults</td><td>Immunity wanes and infections with most coronaviruses generally recur lifelong (<xref rid="bib26" ref-type="bibr">26</xref>)</td></tr><tr><td>Numerous RT-PCR studies investigating coronavirus as potential cause have been negative</td><td>Viral RNA is consistently detected in patient samples by RT-PCR</td></tr><tr><td>Inclusion bodies have been identified in ciliated bronchial epithelium that are targeted by antibodies from KD patients (<xref rid="bib18" ref-type="bibr">18</xref>); virus-like particles found adjacent to inclusion bodies are about 50 nm in diameter (<xref rid="bib17" ref-type="bibr">17</xref>)</td><td>No inclusion bodies are identifiable in bronchial epithelium; virus particles are &#x0223c;120 nm in diameter</td></tr><tr><td>Patients have an antigen-driven immune response that is not directed at coronavirus (<xref rid="bib18" ref-type="bibr">18</xref>)</td><td>Immune response is directed at coronavirus</td></tr><tr><td>Coronary artery aneurysms occur; thrombosis is limited to within aneurysms</td><td>Hypercoagulability with vascular thrombosis at multiple sites is characteristic of SARS-CoV-2 infection; coronary artery aneurysms are not reported in acute SARS-CoV-2 infection; autopsy in the only pediatric patient reported to date with cardiac death from SARS-CoV-2 showed eosinophilic myocarditis with no evidence of vascular inflammation(27)</td></tr><tr><td>Epidemiologic and histologic evidence supports the hypothesis of persistent infection (<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>)</td><td>There is no persistent infection</td></tr><tr><td>Median age of patients with KD-associated shock is 2.8 yrs (<xref rid="bib30" ref-type="bibr">30</xref>)</td><td>Median age of patients with SARS-CoV-2 associated pediatric shock is is 9-10 years (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib7" ref-type="bibr">7</xref>)</td></tr></tbody></table></table-wrap></p><p id="p0035">Many favor the theory that diverse infectious agents (including coronavirus) can trigger a &#x0201c;final common pathway&#x0201d; of immune dysregulation causing KD in a genetically susceptible individual. However, the idea that a genetically predisposed individual who is immunologically susceptible to multiple infections could be triggered only once (since KD rarely recurs) does not fit with our present understanding of human immunology. This hypothesis would also predict that KD could occur at any age, whereas the age distribution of KD is quite classic for a disease caused by a single ubiquitous infectious agent. One also cannot explain the occurrence of well-documented epidemics and outbreaks of KD with geographic wave-like spread of illness (<xref rid="bib15" ref-type="bibr">15</xref>) based on a theory of diverse infectious triggers.</p><p id="p0040">MIS-C cases have appeared during periods of high prevalence of COVID-19 in an individual country, and also appear to decrease following a decline in COVID-19 cases (<xref rid="bib16" ref-type="bibr">16</xref>). It is hoped that when the SARS-CoV-2 pandemic is finally overcome, potentially by vaccination, MIS-C will no longer be a clinical issue. Although the etiologic agent of KD presently remains unclear, research studies support a ubiquitous RNA virus, different from presently known human viruses, that forms intracytoplasmic inclusion bodies in tissues from patients with KD (<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>). We have identified a protein epitope of the putative agent recognized by the antibody response in KD patients, with substantial progress in developing the first-ever serologic assay for KD (<xref rid="bib18" ref-type="bibr">18</xref>). Development of a diagnostic test for KD would enable distinguishing KD from the many infectious and inflammatory conditions in the differential diagnosis (<xref rid="bib19" ref-type="bibr">19</xref>), which presently should include MIS-C. In the meantime, research is urgently needed to identify the pathogenesis of MIS-C, which is currently unknown but bears similarities to the cytokine storm observed in adult patients with COVID-19 during their second week of illness(20).</p><sec id="sec1"><title>Uncited reference</title><p id="p0045">
<xref rid="bib5" ref-type="bibr">5.</xref>, <xref rid="bib6" ref-type="bibr">6.</xref>, <xref rid="bib20" ref-type="bibr">20.</xref>, <xref rid="bib27" ref-type="bibr">27.</xref>.</p></sec></body><back><ref-list id="cebib0010"><title>REFERENCES</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Belhadjer</surname><given-names>Z.</given-names></name><name><surname>Meot</surname><given-names>M.</given-names></name><name><surname>Bajolle</surname><given-names>F.</given-names></name><name><surname>Khraiche</surname><given-names>D.</given-names></name><name><surname>Legendre</surname><given-names>A.</given-names></name><name><surname>Abakka</surname><given-names>S.</given-names></name></person-group><article-title>Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic</article-title><source>Circulation</source><year>2020</year></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Chiotos</surname><given-names>K.</given-names></name><name><surname>Bassiri</surname><given-names>H.</given-names></name><name><surname>Behrens</surname><given-names>E.M.</given-names></name><name><surname>Blatz</surname><given-names>A.M.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Diorio</surname><given-names>C.</given-names></name></person-group><article-title>Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series</article-title><source>J Pediatric Infect Dis Soc</source><year>2020</year></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Riphagen</surname><given-names>S.</given-names></name><name><surname>Gomez</surname><given-names>X.</given-names></name><name><surname>Gonzalez-Martinez</surname><given-names>C.</given-names></name><name><surname>Wilkinson</surname><given-names>N.</given-names></name><name><surname>Theocharis</surname><given-names>P.</given-names></name></person-group><article-title>Hyperinflammatory shock in children during COVID-19 pandemic</article-title><source>Lancet</source><volume>395</volume><issue>10237</issue><year>2020</year><fpage>1607</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">32386565</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Verdoni</surname><given-names>L.</given-names></name><name><surname>Mazza</surname><given-names>A.</given-names></name><name><surname>Gervasoni</surname><given-names>A.</given-names></name><name><surname>Martelli</surname><given-names>L.</given-names></name><name><surname>Ruggeri</surname><given-names>M.</given-names></name><name><surname>Ciuffreda</surname><given-names>M.</given-names></name></person-group><article-title>An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Cabrero-Hernandez</surname><given-names>M.</given-names></name><name><surname>Garcia-Salido</surname><given-names>A.</given-names></name><name><surname>Leoz-Gordillo</surname><given-names>I.</given-names></name><name><surname>Alonso-Cadenas</surname><given-names>J.A.</given-names></name><name><surname>Gochi-Valdovinos</surname><given-names>A.</given-names></name><name><surname>Gonzalez Brabin</surname><given-names>A.</given-names></name></person-group><article-title>Severe SARS-CoV-2 Infection in Children With Suspected Acute Abdomen: A Case Series From a Tertiary Hospital in Spain</article-title><source>Pediatr Infect Dis J</source><year>2020</year></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Waltuch</surname><given-names>T.</given-names></name><name><surname>Gill</surname><given-names>P.</given-names></name><name><surname>Zinns</surname><given-names>L.E.</given-names></name><name><surname>Whitney</surname><given-names>R.</given-names></name><name><surname>Tokarski</surname><given-names>J.</given-names></name><name><surname>Tsung</surname><given-names>J.W.</given-names></name></person-group><article-title>Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department</article-title><source>Am J Emerg Med</source><year>2020</year></element-citation></ref><ref id="bib6a"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>S.</given-names></name></person-group><article-title>Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City</article-title><source>J Pediatr</source><year>2020</year><comment>in press</comment></element-citation></ref><ref id="bib6b"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Capone</surname><given-names>C.</given-names></name></person-group><article-title>Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Disease of Childhood (MIS-C) Associated with SARS-CoV-2 Infection</article-title><source>J Pediatr</source><year>2020</year><comment>in press</comment></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Whittaker</surname><given-names>E.</given-names></name><name><surname>Bamford</surname><given-names>A.</given-names></name><name><surname>Kenny</surname><given-names>J.</given-names></name><name><surname>Kaforou</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>C.E.</given-names></name><name><surname>Shah</surname><given-names>P.</given-names></name></person-group><article-title>Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>R.C.</given-names></name><name><surname>Belay</surname><given-names>E.D.</given-names></name><name><surname>Christensen</surname><given-names>K.Y.</given-names></name><name><surname>Folkema</surname><given-names>A.M.</given-names></name><name><surname>Steiner</surname><given-names>C.A.</given-names></name><name><surname>Schonberger</surname><given-names>L.B.</given-names></name></person-group><article-title>Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007</article-title><source>Pediatr Infect Dis J</source><volume>29</volume><issue>6</issue><year>2010</year><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">20104198</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>N.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Yashiro</surname><given-names>M.</given-names></name><name><surname>Ae</surname><given-names>R.</given-names></name><name><surname>Tsuboi</surname><given-names>S.</given-names></name><name><surname>Aoyama</surname><given-names>Y.</given-names></name></person-group><article-title>Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey</article-title><source>J Epidemiol</source><volume>25</volume><issue>3</issue><year>2015</year><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">25716368</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Toubiana</surname><given-names>J.</given-names></name><name><surname>Poirault</surname><given-names>C.</given-names></name><name><surname>Corsia</surname><given-names>A.</given-names></name><name><surname>Bajolle</surname><given-names>F.</given-names></name><name><surname>Fourgeaud</surname><given-names>J.</given-names></name><name><surname>Angoulvant</surname><given-names>F.</given-names></name></person-group><article-title>Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m2094</fpage><pub-id pub-id-type="pmid">32493739</pub-id></element-citation></ref><ref id="bib10a"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Colomba</surname><given-names>C.</given-names></name><name><surname>LaPlaca</surname><given-names>S.</given-names></name><name><surname>Saporito</surname><given-names>L.</given-names></name><name><surname>Corsella</surname><given-names>G.</given-names></name><name><surname>Ciccia</surname><given-names>F.</given-names></name><name><surname>Medaglia</surname><given-names>A.</given-names></name></person-group><article-title>Intestinal involvement in Kawasaki disease</article-title><source>J Pediatr</source><volume>202</volume><year>2018</year><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">30029859</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Binstadt</surname><given-names>B.A.</given-names></name><name><surname>Levine</surname><given-names>J.C.</given-names></name><name><surname>Nigrovic</surname><given-names>P.A.</given-names></name><name><surname>Gauvreau</surname><given-names>K.</given-names></name><name><surname>Dedeoglu</surname><given-names>F.</given-names></name><name><surname>Fuhlbrigge</surname><given-names>R.C.</given-names></name></person-group><article-title>Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis</article-title><source>Pediatrics</source><volume>116</volume><issue>1</issue><year>2005</year><fpage>e89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15930186</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>K.H.</given-names></name><name><surname>Chang</surname><given-names>S.S.</given-names></name><name><surname>Yu</surname><given-names>C.W.</given-names></name><name><surname>Lin</surname><given-names>S.C.</given-names></name><name><surname>Liu</surname><given-names>S.C.</given-names></name><name><surname>Chao</surname><given-names>H.Y.</given-names></name></person-group><article-title>Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis</article-title><source>BMJ Open</source><volume>5</volume><issue>4</issue><year>2015</year><object-id pub-id-type="publisher-id">e006703</object-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Sohn</surname><given-names>s</given-names></name></person-group><article-title>NT-pro BNP: A new diagnostic screening tool for Kawasaki disease</article-title><source>Korean journal of pediatrics</source><volume>49</volume><issue>5</issue><year>2006</year><fpage>539</fpage><lpage>544</lpage></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Weng</surname><given-names>J.</given-names></name></person-group><article-title>COVID-19 and Kawasaki Disease in Children</article-title><source>Pharmacol Res</source><year>2020</year><fpage>104951</fpage><pub-id pub-id-type="pmid">32464327</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name></person-group><article-title>The Epidemiology and Pathogenesis of Kawasaki Disease</article-title><source>Front Pediatr</source><volume>6</volume><year>2018</year><fpage>374</fpage><pub-id pub-id-type="pmid">30619784</pub-id></element-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="other" id="sref19">Belot A, D A, S R, al. e. SARS-CoV-2-related pediatric inflammatory multisystem syndrome, an epidemiologic study, France, 1 March to 17 May 2020. Euro Surveill. 2020;25(22):pii=2001010.</mixed-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Rand</surname><given-names>K.H.</given-names></name><name><surname>Tretiakova</surname><given-names>M.S.</given-names></name><name><surname>Perlman</surname><given-names>E.J.</given-names></name></person-group><article-title>Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease</article-title><source>J Infect Dis</source><volume>203</volume><issue>7</issue><year>2011</year><fpage>1021</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">21402552</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Arrollo</surname><given-names>D.</given-names></name><name><surname>Gruen</surname><given-names>L.J.</given-names></name><name><surname>Bodnar</surname><given-names>T.</given-names></name><name><surname>Innocentini</surname><given-names>N.</given-names></name></person-group><article-title>A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease</article-title><source>J Infect Dis</source><year>2020</year></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>McCrindle</surname><given-names>B.W.</given-names></name><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Bolger</surname><given-names>A.F.</given-names></name><name><surname>Gewitz</surname><given-names>M.</given-names></name></person-group><article-title>Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association</article-title><source>Circulation</source><volume>135</volume><issue>17</issue><year>2017</year><fpage>e927</fpage><lpage>e999</lpage><pub-id pub-id-type="pmid">28356445</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>D.M.</given-names></name><name><surname>Brink</surname><given-names>E.W.</given-names></name><name><surname>Nitzkin</surname><given-names>J.L.</given-names></name><name><surname>Hall</surname><given-names>C.B.</given-names></name><name><surname>Wulff</surname><given-names>H.</given-names></name><name><surname>Berkowitz</surname><given-names>I.D.</given-names></name></person-group><article-title>Kawasaki syndrome: description of two outbreaks in the United States</article-title><source>N Engl J Med</source><volume>304</volume><issue>26</issue><year>1981</year><fpage>1568</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">7231502</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>A.G.</given-names></name><name><surname>Melish</surname><given-names>M.E.</given-names></name><name><surname>Hicks</surname><given-names>R.</given-names></name><name><surname>Palumbo</surname><given-names>N.E.</given-names></name></person-group><article-title>An epidemic of Kawasaki syndrome in Hawaii</article-title><source>J Pediatr</source><volume>100</volume><issue>4</issue><year>1982</year><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">7062202</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Quiat</surname><given-names>D.</given-names></name><name><surname>Kula</surname><given-names>T.</given-names></name><name><surname>Shimizu</surname><given-names>C.</given-names></name><name><surname>Kanegaye</surname><given-names>J.T.</given-names></name><name><surname>Tremoulet</surname><given-names>A.H.</given-names></name><name><surname>Pitkowsky</surname><given-names>Z.</given-names></name></person-group><article-title>High-Throughput Screening of Kawasaki Disease Sera for Antiviral Antibodies</article-title><source>J Infect Dis</source><year>2020</year></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>L'Huillier</surname><given-names>A.G.</given-names></name><name><surname>Brito</surname><given-names>F.</given-names></name><name><surname>Wagner</surname><given-names>N.</given-names></name><name><surname>Cordey</surname><given-names>S.</given-names></name><name><surname>Zdobnov</surname><given-names>E.</given-names></name><name><surname>Posfay-Barbe</surname><given-names>K.M.</given-names></name></person-group><article-title>Identification of Viral Signatures Using High-Throughput Sequencing on Blood of Patients With Kawasaki Disease</article-title><source>Front Pediatr</source><volume>7</volume><year>2019</year><fpage>524</fpage><pub-id pub-id-type="pmid">31921732</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name></person-group><article-title>Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63</article-title><source>Clin Diagn Lab Immunol</source><volume>12</volume><issue>11</issue><year>2005</year><fpage>1317</fpage><lpage>1321</lpage><pub-id pub-id-type="pmid">16275947</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Callow</surname><given-names>K.A.</given-names></name><name><surname>Parry</surname><given-names>H.F.</given-names></name><name><surname>Sergeant</surname><given-names>M.</given-names></name><name><surname>Tyrrell</surname><given-names>D.A.</given-names></name></person-group><article-title>The time course of the immune response to experimental coronavirus infection of man</article-title><source>Epidemiol Infect</source><volume>105</volume><issue>2</issue><year>1990</year><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">2170159</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Craver</surname><given-names>R.</given-names></name><name><surname>Huber</surname><given-names>S.</given-names></name><name><surname>Sandomirsky</surname><given-names>M.</given-names></name><name><surname>McKenna</surname><given-names>D.</given-names></name><name><surname>Schieffelin</surname><given-names>J.</given-names></name><name><surname>Finger</surname><given-names>L.</given-names></name></person-group><article-title>Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)</article-title><source>Fetal Pediatr Pathol</source><year>2020</year><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Nagao</surname><given-names>Y.</given-names></name><name><surname>Urabe</surname><given-names>C.</given-names></name><name><surname>Nakamura</surname><given-names>H.</given-names></name><name><surname>Hatano</surname><given-names>N.</given-names></name></person-group><article-title>Predicting the characteristics of the aetiological agent for Kawasaki disease from other paediatric infectious diseases in Japan</article-title><source>Epidemiol Infect</source><volume>144</volume><issue>3</issue><year>2016</year><fpage>478</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">26201398</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Garcia</surname><given-names>F.L.</given-names></name><name><surname>Fox</surname><given-names>L.M.</given-names></name><name><surname>Kos</surname><given-names>I.M.</given-names></name></person-group><article-title>RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease</article-title><source>PloS one</source><volume>3</volume><issue>2</issue><year>2008</year><object-id pub-id-type="publisher-id">e1582</object-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Kanegaye</surname><given-names>J.T.</given-names></name><name><surname>Wilder</surname><given-names>M.S.</given-names></name><name><surname>Molkara</surname><given-names>D.</given-names></name><name><surname>Frazer</surname><given-names>J.R.</given-names></name><name><surname>Pancheri</surname><given-names>J.</given-names></name><name><surname>Tremoulet</surname><given-names>A.H.</given-names></name></person-group><article-title>Recognition of a Kawasaki disease shock syndrome</article-title><source>Pediatrics</source><volume>123</volume><issue>5</issue><year>2009</year><fpage>e783</fpage><lpage>e789</lpage><pub-id pub-id-type="pmid">19403470</pub-id></element-citation></ref></ref-list><fn-group><fn id="d33e433"><p id="ntpara0010">Funded by the National Institutes of Health R21AI140029 (to A.R.), the Feitler Family, the Max Goldenberg Foundation, and the Center for Kawasaki Disease at the Ann &#x00026; Robert H. Lurie Children&#x02019;s Hospital of Chicago. A.R. is co-inventor on a provisional patent application related to antibodies and antigens of Kawasaki Disease, serial number 62/811,930.</p></fn></fn-group></back></article>